TRAVERE THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-25.5M | $-321.5M | $-111.4M | $-278.5M | $-180.1M | $-169.4M | $-146.4M | $-102.7M |
| Depreciation & Amortization | $60.7M | $43.6M | $38.5M | $20.7M | $12.7M | $24.6M | $20.4M | $18.7M |
| Depreciation | $1.5M | $1.8M | $2.2M | $2.1M | $1.7M | $2.1M | $700.0K | $600.0K |
| Amortization | $59.2M | $41.7M | $36.3M | $18.6M | $11.0M | $22.4M | $19.7M | $18.0M |
| Stock-Based Compensation | $44.9M | $36.9M | $44.2M | $38.1M | $29.6M | $23.6M | $21.1M | $19.8M |
| Net Cash from Operating Activities | $37.8M | $-237.5M | $-280.0M | $-186.3M | $-14.8M | $-42.7M | $-58.2M | $-25.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $668.0K | $191.0K | $5.1M | $6.8M | $195.0K | $727.0K |
| Business Acquisitions | — | — | — | $0 | $0 | $95.3M | $0 | $0 |
| Net Cash from Investing Activities | $27.9M | $99.3M | $55.8M | $-32.6M | $-137.6M | $-61.3M | $19.9M | $-203.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-33.5M | $139.4M | $218.8M | $117.6M | $231.7M | $127.7M | $-2.1M | $231.9M |
| Net Change in Cash | $34.5M | $359.0K | $-3.5M | $-104.1M | $81.0M | $22.3M | $-40.4M | $3.5M |
| Free Cash Flow | — | — | $-280.7M | $-186.5M | $-19.9M | $-49.5M | $-58.4M | $-25.7M |